BVF Inc. IL boosted its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 23.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 19,995,332 shares of the biopharmaceutical company’s stock after buying an additional 3,846,153 shares during the period. Lexicon Pharmaceuticals makes up approximately 1.3% of BVF Inc. IL’s […]
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 21,980,000 shares, a growth of 12.7% from the October 15th total of 19,500,000 shares. Based on an average trading volume of 2,210,000 shares, […]
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) had its price target dropped by equities researchers at Citigroup from $8.00 to $5.00 in a report issued on Friday, FlyOnTheWall reports. Citigroup’s price target would suggest a potential upside of 167.38% from the stock’s current price. Separately, StockNews.com raised Lexicon Pharmaceuticals to a “sell” rating in a […]
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) CEO Lonnel Coats acquired 40,000 shares of the company’s stock in a transaction on Thursday, June 22nd. The shares were bought at an average price of $2.31 per share, for a total transaction of $92,400.00. Following the completion of the purchase, the chief executive officer now owns 784,359 […]
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) CFO Jeffrey L. Wade bought 12,000 shares of the company’s stock in a transaction on Tuesday, June 20th. The stock was purchased at an average cost of $2.33 per share, for a total transaction of $27,960.00. Following the completion of the transaction, the chief financial officer now owns […]